Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript

Aug 6, 2026 / 09:00 PM GMT

Release Date Price: €2.82

Transcript 8-K10-Q

Key Points

Positve

CytomX Therapeutics Inc (CTMX) is aggressively advancing its lead asset, Varetta M, a first-in-class EPCAM-targeting ADC, with a clear path toward a registrational study in late-line colorectal cancer (CRC) by the first half of 2027.
The company is broadening Varetta M's potential by initiating phase 1 expansion cohorts in additional GI cancers (gastric, pancreatic, and biliary tract), positioning it as a potential pan-tumor therapy.
Strong clinical progress is highlighted by preliminary PFS data of 6.8-7.1 months at the top two doses in late-line CRC, which compares favorably to existing benchmarks of 4.5-5.5 months for standard of care.
The company has a solid financial runway, projecting cash to last until at least the second half of 2028, which supports advancing Varetta M through key clinical milestones.
The expanded collaboration with Regeneron, including a $37 million payment, validates CytomX's proprietary masking technology and provides additional non-dilutive funding.
The company is strengthening its leadership team with key appointments in regulatory affairs, legal, and a new board member with deep GI oncology expertise, preparing for late-stage development.

Negative

Total revenue decreased significantly to $1.4 million in Q2 2026 from $18.7 million in Q2 2025, due to the conclusion of major collaborations with BMS and Aelis.
Operating expenses increased to $25.2 million in Q2 2026 from $19.9 million in Q2 2025, driven by higher R&D costs for manufacturing and personnel, which could pressure future cash flow.
The company faces a key safety risk with Varetta M, as the rate of grade 3 diarrhea is a concern; while initial prophylaxis data is encouraging, the acceptable threshold is up to 20%, which could limit its use in earlier lines of therapy.
The development strategy for the first registrational study is still undecided (third vs. fourth line), and the company is awaiting more mature data, including overall survival, to make a final decision.
The company is enrolling unselected patients in CRC but will need to screen for EPCAM expression in pancreatic and biliary tract cancers, which could slow enrollment and limit the addressable patient population in those indications.
The initial data for the bevacizumab combination and the new phase 1/2 trial in second-line CRC will not be available until the first half of 2027, leaving a significant gap in clinical updates.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CTMX.OQ - CytomX Therapeutics, Inc.
Q2 2026 CytomX Therapeutics Inc Earnings Call
Aug 06, 2026 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, everyone.

Thank you for standing by.

Welcome to the Cytomics Therapeutics, second quarter 2026 financial res Hall is recorded.

I would now like to hand the call over to host for today, Chris Ogden, Cytomic's Chief Financial Officer, please go ahead.

Thank you, good afternoon and thank you for joining us.

Before we begin, I would like to remind everyone that during this call we'll be making forward-looking statements.

Because forwardl statements to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control.

Important risks and uncertainties are set forth in our

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.